Search published articles


Showing 3 results for Transfusion Dependent

Keikhaei B, Shariati G, Abolghasemi H,
Volume 7, Issue 3 (4-2015)
Abstract

Background: Beta thalassemia gene mutations are among common mutations in southwest Iran. However, Hemoglobin E (Hb E) and Hb E/β⁰ thalassemia account for a small number of hemoglobinopathies in Iran. This is the first study to directly address the existence of Hb E and consequently Hb E/β⁰ thalassemia in southwest Iran. Methods: This retrospective study discovered seven cases of Hb E/β⁰ thalassemia among 700 patients with hemoglobinopathies referring to Health Institute and Research Center for Thalassemia and Hemoglobinopathy in southwest Iran. EDTA and clot blood samples were obtained and analyzed for complete blood counts, hemoglobin electrophoresis, LDH, bilirubin, ferritin and amplification refractory mutation system (ARMS) technique by polymerase chain reaction (PCR) and DNA sequencing. Results: Out of 700 cases, seven patients with Hb E/β⁰ thalassemia were detected (1%). Four patients were classified into non-transfused dependent Hb E/β⁰ thalassemia and three cases were classified into transfusion dependent Hb E/β⁰ thalassemia group. Alpha thalassemia (deletional and non-deletional) and XmnI gene polymorphism were not found in either of cases. Conclusion: Hb E/β Thalassemia is not a common hemoglobin disorder in southwest Iran. Phenotype heterogeneity is common in Iranian patients from a mild asymptomatic anemia to severe anemia that can be presented in the early years of life. This was the first report of Hb E/β⁰ thalassemia from Iran. Keywords: Hb E/β⁰ Thalassemia, Southwest Iran, Transfusion dependent, Non-transfusion dependent, Hb E mutation.
Dr Nahid Hashemi-Madani, Dr Neda Rahimian, Dr Mohammad E. Khamseh, Dr Pooya Faranoush, Dr Mojtaba Malek, Dr Fariba Ghasemi, Dr Negin Sadighnia, Dr Mohammad Reza Foroughi-Gilvaee, Dr Seyyed Morteza Alavi, Dr Mohammad Javad Mashayekhnia, Dr Mahdi Bashizade, Dr Mohammad Reza Roudaki Sarvendani, Dr Elham Ebrahimi, Dr Mohammad Faranoush,
Volume 15, Issue 2 (6-2023)
Abstract

Iron overload can adversely affect thyroid and parathyroid function in patients with transfusion-dependent thalassemia. Iron deposition in both glands or the pituitary gland, which controls thyroid function, can lead to their destruction and dysfunction. Hypothyroidism can cause symptoms such as fatigue, weight gain, and depression, while hypoparathyroidism can cause symptoms such as numbness and tingling in the hands and feet, muscle cramps, and seizures. Regular thyroid and parathyroid function monitoring is essential in thalassemia patients to detect any dysfunction early and provide appropriate treatment. Treatment may include medications to replace thyroid hormone or calcium and vitamin D supplements to manage hypoparathyroidism. A comprehensive approach to managing endocrine complications in thalassemia patients can improve outcomes and quality of life for these individuals. To provide professional healthcare members with clear and concise recommendations for diagnosing and treating hypothyroidism and hypoparathyroidism in transfusion dependent thalassemia patients, a practical national guideline should be developed.


Dr Fariba Ghassemi, Dr Mohammad E. Khamseh, Dr Negin Sadighnia, Dr Mojtaba Malek, Dr Nahid Hashemi-Madani, Dr Neda Rahimian, Dr Pooya Faranoush, Dr Ali Elahinia, Dr Vahid Saeedi, Dr Dorsa Fallah Azad, Dr Mohammad Faranoush,
Volume 16, Issue 1 (3-2024)
Abstract

ntroduction: Thalassemia, particularly α and β types, are characterized by mutations causing varied clinical manifestations such as anemia, skeletal deformities, and iron accumulation. Patients with transfusion-dependent thalassemia (TDTs) often face growth and puberty complications, which are influenced by the disease’s type and severity. These disruptions not only result from chronic anemia, iron chelation therapy, and endocrinopathies but also significantly impact the patient’s quality of life.
Methods: A comprehensive guideline was formulated through a systematic literature review and stakeholder engagements. The protocol emphasizes diagnosing and managing growth and puberty disorders in TDT patients, integrating consistent monitoring, documentation, and patient-specific assessments.
Results: The guideline proposes a detailed monitoring schedule from birth to adulthood, focusing on growth velocity norms and referral criteria to pediatric endocrinologists. It outlines protocols for hormone treatments in cases of delayed or arrested puberty, with distinctions for boys and girls. The treatment approach is multidisciplinary, combining growth monitoring, hormone therapy, and potential surgical interventions. The complexities demand continuous management, with treatment plans tailored to individual patient needs.
Conclusions: The research provides a pivotal national protocol for addressing growth and puberty anomalies in TDT patients, aiming to enhance their well-being and standardize care. The emphasis on proactive, individualized strategies will bolster healthcare outcomes and reduce associated costs.


Page 1 from 1     

© 2025 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb